FRM 0334

Drug Profile

FRM 0334

Alternative Names: EVP-0334; FRM0334

Latest Information Update: 22 Feb 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MethylGene
  • Developer EnVivo Pharmaceuticals; FORUM Pharmaceuticals; Mirati Therapeutics
  • Class Antidementias; Nootropics; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alzheimer's disease; Dementia; Parkinson's disease

Most Recent Events

  • 22 Feb 2018 Discontinued - Phase-II for Dementia (In the elderly, In adults) in United Kingdom, France, Belgium, Netherlands, Netherlands, Italy, USA (PO) before February 2018
  • 30 Dec 2015 Phase-II clinical trials in Dementia (In the elderly, In adults) in Belgium, France and United Kingdom (PO)
  • 16 Nov 2014 Discontinued - Phase-I for Parkinson's disease in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top